These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 27756336)

  • 1. Identification of BRCA1-like triple-negative breast cancers by quantitative multiplex-ligation-dependent probe amplification (MLPA) analysis of BRCA1-associated chromosomal regions: a validation study.
    Gross E; van Tinteren H; Li Z; Raab S; Meul C; Avril S; Laddach N; Aubele M; Propping C; Gkazepis A; Schmitt M; Meindl A; Nederlof PM; Kiechle M; Lips EH
    BMC Cancer; 2016 Oct; 16(1):811. PubMed ID: 27756336
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantitative copy number analysis by Multiplex Ligation-dependent Probe Amplification (MLPA) of BRCA1-associated breast cancer regions identifies BRCAness.
    Lips EH; Laddach N; Savola SP; Vollebergh MA; Oonk AM; Imholz AL; Wessels LF; Wesseling J; Nederlof PM; Rodenhuis S
    Breast Cancer Res; 2011 Oct; 13(5):R107. PubMed ID: 22032731
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BRCAness and Prognosis in Triple-Negative Breast Cancer Patients Treated with Neoadjuvant Chemotherapy.
    Tanino H; Kosaka Y; Nishimiya H; Tanaka Y; Minatani N; Kikuchi M; Shida A; Waraya M; Katoh H; Enomoto T; Sengoku N; Kajita S; Hoffman RM; Watanabe M
    PLoS One; 2016; 11(12):e0165721. PubMed ID: 27935989
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the BRCAness phenotype and its correlations with clinicopathological features in triple-negative breast cancers.
    Tian T; Shan L; Yang W; Zhou X; Shui R
    Hum Pathol; 2019 Feb; 84():231-238. PubMed ID: 30339969
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Correlation Between PARP1 and BRCA1 in AR Positive Triple-negative Breast Cancer.
    Luo J; Jin J; Yang F; Sun Z; Zhang W; Shi Y; Xu J; Guan X
    Int J Biol Sci; 2016; 12(12):1500-1510. PubMed ID: 27994514
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biological and clinical significance of PARP1 protein expression in breast cancer.
    Green AR; Caracappa D; Benhasouna AA; Alshareeda A; Nolan CC; Macmillan RD; Madhusudan S; Ellis IO; Rakha EA
    Breast Cancer Res Treat; 2015 Jan; 149(2):353-62. PubMed ID: 25528020
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BRCA1 deficiency is a recurrent event in early-onset triple-negative breast cancer: a comprehensive analysis of germline mutations and somatic promoter methylation.
    Brianese RC; Nakamura KDM; Almeida FGDSR; Ramalho RF; Barros BDF; Ferreira ENE; Formiga MNDC; de Andrade VP; de Lima VCC; Carraro DM
    Breast Cancer Res Treat; 2018 Feb; 167(3):803-814. PubMed ID: 29116469
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BRCAness digitalMLPA profiling predicts benefit of intensified platinum-based chemotherapy in triple-negative and luminal-type breast cancer.
    Lips EH; Benard-Slagter A; Opdam M; Scheerman CE; Wesseling J; Hogervorst FBL; Linn SC; Savola S; Nederlof PM
    Breast Cancer Res; 2020 Jul; 22(1):79. PubMed ID: 32711554
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epigenetic Inactivation of BRCA1 Through Promoter Hypermethylation and Its Clinical Importance in Triple-Negative Breast Cancer.
    Yamashita N; Tokunaga E; Kitao H; Hitchins M; Inoue Y; Tanaka K; Hisamatsu Y; Taketani K; Akiyoshi S; Okada S; Oda Y; Saeki H; Oki E; Maehara Y
    Clin Breast Cancer; 2015 Dec; 15(6):498-504. PubMed ID: 26195437
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BRCA1 promoter hypermethylation, 53BP1 protein expression and PARP-1 activity as biomarkers of DNA repair deficit in breast cancer.
    Jacot W; Thezenas S; Senal R; Viglianti C; Laberenne AC; Lopez-Crapez E; Bibeau F; Bleuse JP; Romieu G; Lamy PJ
    BMC Cancer; 2013 Nov; 13():523. PubMed ID: 24191908
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BRCA1/2-negative hereditary triple-negative breast cancers exhibit BRCAness.
    Domagala P; Hybiak J; Cybulski C; Lubinski J
    Int J Cancer; 2017 Apr; 140(7):1545-1550. PubMed ID: 27943282
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Using next-generation sequencing to redefine BRCAness in triple-negative breast cancer.
    Lin PH; Chen M; Tsai LW; Lo C; Yen TC; Huang TY; Chen CK; Fan SC; Kuo SH; Huang CS
    Cancer Sci; 2020 Apr; 111(4):1375-1384. PubMed ID: 31958182
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BRCAness is beneficial for indicating triple negative breast cancer patients resistant to taxane.
    Ishikawa T; Narui K; Tanabe M; Kida K; Oba MS; Yamada A; Ichikawa Y; Endo I
    Eur J Surg Oncol; 2016 Jul; 42(7):999-1001. PubMed ID: 27041672
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanisms of Therapy Resistance in Patient-Derived Xenograft Models of BRCA1-Deficient Breast Cancer.
    Ter Brugge P; Kristel P; van der Burg E; Boon U; de Maaker M; Lips E; Mulder L; de Ruiter J; Moutinho C; Gevensleben H; Marangoni E; Majewski I; Józwiak K; Kloosterman W; van Roosmalen M; Duran K; Hogervorst F; Turner N; Esteller M; Cuppen E; Wesseling J; Jonkers J
    J Natl Cancer Inst; 2016 Nov; 108(11):. PubMed ID: 27381626
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Frequent incidence of BARD1-truncating mutations in germline DNA from triple-negative breast cancer patients.
    De Brakeleer S; De Grève J; Desmedt C; Joris S; Sotiriou C; Piccart M; Pauwels I; Teugels E
    Clin Genet; 2016 Mar; 89(3):336-40. PubMed ID: 26010302
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BRCA1 promoter methylation is a marker of better response to anthracycline-based therapy in sporadic TNBC.
    Ignatov T; Poehlmann A; Ignatov A; Schinlauer A; Costa SD; Roessner A; Kalinski T; Bischoff J
    Breast Cancer Res Treat; 2013 Sep; 141(2):205-12. PubMed ID: 24026861
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel crosstalk between BRCA1 and poly (ADP-ribose) polymerase 1 in breast cancer.
    Li D; Bi FF; Chen NN; Cao JM; Sun WP; Zhou YM; Li CY; Yang Q
    Cell Cycle; 2014; 13(21):3442-9. PubMed ID: 25485588
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of AR antagonist combined with PARP1 inhibitor on sporadic triple-negative breast cancer bearing AR expression and methylation-mediated BRCA1 dysfunction.
    Sang M; Meng L; Ma C; Liu S; Sang M; Chang S; Liu F; Lian Y; Geng C
    Biomed Pharmacother; 2019 Mar; 111():169-177. PubMed ID: 30580238
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polymorphisms in poly (ADP-ribose) polymerase-1 (PARP1) promoter and 3' untranslated region and their association with PARP1 expression in breast cancer patients.
    Zhai L; Li S; Li H; Zheng Y; Lang R; Fan Y; Gu F; Guo X; Zhang X; Fu L
    Int J Clin Exp Pathol; 2015; 8(6):7059-71. PubMed ID: 26261599
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nuclear PARP1 expression and its prognostic significance in breast cancer patients.
    Mazzotta A; Partipilo G; De Summa S; Giotta F; Simone G; Mangia A
    Tumour Biol; 2016 May; 37(5):6143-53. PubMed ID: 26614429
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.